S1418/BR006 A Randomized Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with > 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy.

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Triple Negative Breast Cancer
  • Age: Between 18 - 90 Years
  • Gender: Male or Female
  • Other Inclusion Criteria:

    1.  Patients must have histologically confirmed ER-, PR- and HER2-negative (triple-negative, TNBC) with residual invasive breast cancer (positive lymph nodes or at least 1 cm invasive cancer in the breast)

     

    2.  Patients must not have metastatic disease

     

    3.  Patients must have had neoadjuvant chemotherapy followed by surgery

     

    4.  Additional chemotherapy and/or radiation is allowed after surgery, but enrollment must occur shortly after

     


You may not be eligible for this study if the following are true:

  • 1.  Patients with a history of (non-infectious) pneumonitis that required steroid or evidence of active pneumonitis

     

    2.  Patients with certain autoimmune diseases

     

    3.  Patients who have had prior immunotherapy with anti-PD-L1, anti-PD-1, anti-CTLA4 or similar drugs




If you are registered as a volunteer, please login to the dashboard to send referrals.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.